

## Total number of voting rights and shares

**Nantes, December 6, 2016** – Pursuant to article L.233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement Général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority), OSE Immunotherapeutics (ISIN : FR0012127173 ; Mnémo : OSE), a biotechnology company developing immunotherapies of activation or regulation in immuno-oncology, auto-immune diseases and transplantation, informs its shareholders of the number of voting rights and shares on the date of November 30, 2016.

Date	Total number of outstanding shares	Total number of voting rights
November 30, 2016	14.250.753	Theoretical <sup>1</sup> : 14.250.753 Exercisable: 14.216.626

<sup>1</sup> *Theoretical voting rights = total number of voting rights attached to the total number of shares, including treasury shares and private voting shares.*

### ABOUT OSE IMMUNOTHERAPEUTICS

#### *A world leader in activation and regulation immunotherapies*

OSE Immunotherapeutics is a biotechnology company led by world-class immunologists and focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology, auto-immune diseases and transplantation. The company has a balanced portfolio of first-in-class products with a diversified risk profile ranging from clinical phase 3 registration trials to R&D:

- Tedopi®, a combination of 10 optimized neo-epitopes to induce specific T activation in immuno-oncology - currently in registration Phase 3 trial advanced NSCLC HLA A2+ patients EU /US - Orphan Status in the US - registration expected in 2019 - a Phase 2 with Tedopi® in combination with a checkpoint inhibitor in NSCLC is considered in 2017 - the product is also considered in other cancer indications.
- FR104, CD28-antagonist in immunotherapy - Phase 1 trial completed - targets autoimmune diseases and transplantation - licensed to J&J to pursue clinical development
- Effi-7, interleukin receptor 7 antagonist - in preclinical development for inflammatory bowel diseases and other autoimmune diseases
- Effi-DEM, new generation checkpoint inhibitor targeting the SIRP-α receptor on the strategic SIRP-α/CD47 pathway - in preclinical development for immuno-oncology
- R&D: candidates targeting new receptors in immuno-oncology

Given the targeted medical needs, these products show a real potential of blockbuster and give the company the ability to enter into global agreements at different stages of development with major pharmaceutical actors, such as the one signed on FR104 product with the J&J Group.

OSE Immunotherapeutics aims for the field of immunotherapy, a highly promising growing market. By 2023 Immunotherapy of cancer could represent nearly 60% of treatments against less than 3% at present \* and the projected market is estimated at \$ 67 billion in 2018 \*\*.

There are more than 80 autoimmune diseases that represent a significant market including major actors in the pharmaceutical industry with sales upper 10 billion \$ for the main products. The medical need remains today highly unmet and requires the provision of new innovative and suitable products involved in the regulation of the immune system.



## **Contacts**

### **OSE Immunotherapeutics**

Sylvie Détry

[sylvie.detry@ose-immuno.com](mailto:sylvie.detry@ose-immuno.com)

+33 143 297 857

### **Contacts media: Alize RP**

Florence Portejoie & Caroline Carmagnol

[oseimmuno@alizerp.com](mailto:oseimmuno@alizerp.com)

+33 647 389 004